Sanofi (NASDAQ:SNY) has signed an exclusive rights deal with Roche (OTCQX:RHHBY) for ‘Tamiflu’ in the U.S., which is used for the prevention and treatment of flu.
“This is a strategic and important transaction for us as we strive to continually bring innovations to the market,” said Alan Main, executive vice president of Sanofi’s consumer healthcare division.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.